menu
    • menu

    Company profile for Emalex Bioscience

    NEW Drugs in Dev: 3
    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Sigma-Aldrich empowers scientific discovery with top-quality solutions to accelerate research, innovation, and better health worldwide.

    Virtual Booth

    Contact Supplier

    Athena Pharmaceutiques is a Partner of Choice for Drug Delivery & Life Cycle Management.

    Virtual Booth

    Contact Supplier

    TransoPharm USA works in the Sourcing and Management of Active Pharmaceutical Ingredients.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Emalex is committed to addressing unmet medical needs by developing novel treatments for central nervous system movement disorders and fluency disorders. We partner with patient advocacy organizations to raise awareness of these disorders and support their education outreach and communication efforts.Emalex Biosciences, LLC is a biopharmaceutical company dedicated to the development of new treatments for rare and orphan neurol...
    Emalex is committed to addressing unmet medical needs by developing novel treatments for central nervous system movement disorders and fluency disorders. We partner with patient advocacy organizations to raise awareness of these disorders and support their education outreach and communication efforts.Emalex Biosciences, LLC is a biopharmaceutical company dedicated to the development of new treatments for rare and orphan neurological conditions. Ecopipam, its first development candidate, is a novel compound that has been studied as a potential treatment for many central nervous system (CNS) disorders, including pediatric Tourette Syndrome.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Emalex BioscienceUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    330 N. Wabash, Suite 3500, Chicago, IL 60611
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://emalexbiosciences.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/emalex-biosciences/
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Teva Closes Emalex Acquisition, Boosting Neuroscience Pipeline
    Teva Closes Emalex Acquisition, Boosting Neuroscience Pipeline

    10 Jun 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/06/10/3309960/0/en/teva-closes-acquisition-of-emalex-biosciences-strengthening-late-stage-neuroscience-pipeline-and-advancing-pivot-to-growth-strategy.html

    GLOBENEWSWIRE
    10 Jun 2026
    Share Share
    Phase III Drug Shows Promise in Managing Tourette Syndrome
    Phase III Drug Shows Promise in Managing Tourette Syndrome

    26 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/new-med-to-manage-tourette-syndrome-shows-promise-in-phase-iii-clinical-trial-302782064.html

    PR NEWSWIRE
    26 May 2026
    Share Share
    Teva Acquires Emalex, Adding NDA-Ready Therapy
    Teva Acquires Emalex, Adding NDA-Ready Therapy

    29 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/29/3283566/0/en/teva-to-acquire-emalex-biosciences-adding-nda-ready-first-in-class-therapy-to-neuroscience-pipeline-and-accelerating-teva-s-pivot-to-growth-strategy.html

    GLOBENEWSWIRE
    29 Apr 2026
    Share Share
    Emalex Wins US Patent for Oral Ecopipam Formulation
    Emalex Wins US Patent for Oral Ecopipam Formulation

    09 Apr 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260407152501/en/Emalex-Receives-U.S.-Patent-for-Orally-Disintegrating-Ecopipam-Formulation

    BUSINESSWIRE
    09 Apr 2026
    Share Share
    Emalex Gets FDA OK for Tourette Drug Expanded Access Program
    Emalex Gets FDA OK for Tourette Drug Expanded Access Program

    08 Oct 2025

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20251007679744/en/Emalex-Biosciences-Expanded-Access-Program-for-Investigational-Tourette-Syndrome-Drug-Receives-FDA-Authorization

    BUSINESSWIRE
    08 Oct 2025
    Share Share
    Emalex eyes potential Tourette approval after phase 3 win
    Emalex eyes potential Tourette approval after phase 3 win

    26 Feb 2025

    // FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/emalex-dopamine-blocker-stops-tourette-syndrome-relapse-phase-3-win

    FIERCE BIOTECH
    26 Feb 2025
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search